ANAB
AnaptysBio, Inc. [ANAB] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ANAB Stock Summary
Top 10 Correlated Stocks
ANAB
In the News
Down -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. (ANAB) Looks Ripe for a Turnaround
AnaptysBio, Inc. (ANAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Anaptys Announces Participation in November Investor Conferences
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team are scheduled to participate in multiple upcoming investor conferences in November:
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023. The oral presentation will focus on ANB032's previously reported healthy volunteer Phase 1 data and the trial-in-progress poster presentation will focus on ANB032's Phase 2b study in moderate to severe atopic dermatitis.
AnaptysBio's skin disease drug meets main goal in late-stage study
AnaptysBio Inc said on Monday its experimental drug to treat a type of rare skin disease met the main goal in a late-stage study.
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will present at the Stifel 2023 Immunology and Inflammation Virtual Summit later this month.
AnaptysBio: Despite Early Successes, Current Situation Does Not Impress
AnaptysBio, Inc. had major deals with big pharma in past years. However, its current programs are not that convincing. They have a lot of cash from earlier deals.
AnaptysBio Announces Participation in Upcoming Investor Conferences
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of its senior management team are scheduled to participate in both of the upcoming investor conferences below:
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $1.31 per share a year ago.
AnaptysBio: Upside Could Be Lying Ahead Very Nicely
US-listed biotech stocks are trading even lower than before on fears of a banking system collapse, creating an opportunity to add to positions and take advantage of attractive levels. AnaptysBio, Inc. appears to be one of the US-listed biotech stocks worth investing in due to its low stock price combined with some interesting positive catalysts in its treatment pipeline.
GSK's Jemperli Effective Against First-Line Endometrial Cancer
A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
ANAB Financial details
ANAB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.2 | 0.3 | 2.75 | 2.3 | 0.37 | |
| Net income per share | -2.5 | -3.6 | -0.73 | -2.08 | -4.57 | |
| Operating cash flow per share | -1.97 | -2.57 | -0.52 | -1.67 | -2.61 | |
| Free cash flow per share | -2.01 | -2.6 | -0.54 | -1.72 | -2.63 | |
| Cash per share | 17.31 | 13.83 | 14.42 | 19.98 | 15.67 | |
| Book value per share | 19.71 | 14.97 | 14.53 | 12.99 | 9.31 | |
| Tangible book value per share | 19.71 | 14.97 | 14.53 | 12.99 | 9.31 | |
| Share holders equity per share | 19.71 | 14.97 | 14.53 | 12.99 | 9.31 | |
| Interest debt per share | 0.4 | 0.12 | 0.01 | 0.82 | 1.44 | |
| Market cap | 1.57B | 439.71M | 586.99M | 953.23M | 872.83M | |
| Enterprise value | 1.47B | 270.94M | 336.88M | 478.45M | 820.98M | |
| P/E ratio | -25.53 | -4.52 | -29.47 | -16.67 | -6.78 | |
| Price to sales ratio | 314.78 | 54.96 | 7.83 | 15.09 | 84.85 | |
| POCF ratio | -32.45 | -6.33 | -41.46 | -20.76 | -11.86 | |
| PFCF ratio | -31.75 | -6.25 | -39.86 | -20.16 | -11.8 | |
| P/B Ratio | 3.24 | 1.09 | 1.48 | 2.67 | 3.33 | |
| PTB ratio | 3.24 | 1.09 | 1.48 | 2.67 | 3.33 | |
| EV to sales | 293.71 | 33.87 | 4.49 | 7.57 | 79.81 | |
| Enterprise value over EBITDA | -24.4 | -2.81 | -17.39 | -8.49 | -7.63 | |
| EV to operating cash flow | -30.28 | -3.9 | -23.8 | -10.42 | -11.16 | |
| EV to free cash flow | -29.63 | -3.85 | -22.88 | -10.12 | -11.1 | |
| Earnings yield | -0.04 | -0.22 | -0.03 | -0.06 | -0.15 | |
| Free cash flow yield | -0.03 | -0.16 | -0.03 | -0.05 | -0.08 | |
| Debt to equity | 0.02 | 0.01 | 0 | 0.06 | 0.07 | |
| Debt to assets | 0.02 | 0.01 | 0 | 0.03 | 0.03 | |
| Net debt to EBITDA | 1.75 | 1.75 | 12.91 | 8.43 | 0.48 | |
| Current ratio | 19.89 | 12.79 | 20.01 | 34.4 | 17.16 | |
| Interest coverage | -40.39 | -103.2 | 0 | -39.18 | -5.46 | |
| Income quality | 0.79 | 0.71 | 0.71 | 0.79 | 0.57 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.11 | 2.01 | 0.25 | 0.34 | 3.56 | |
| Research and developement to revenue | 11.24 | 12.42 | 1.07 | 1.56 | 8.63 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.01 | 0.04 | 0.03 | 0 | |
| Capex to revenue | -0.21 | -0.1 | -0.01 | -0.02 | -0.03 | |
| Capex to depreciation | -3.37 | -1.57 | -1.02 | -0.65 | -0.15 | |
| Stock based compensation to revenue | 1.99 | 1.55 | 0.15 | 0.24 | 2.66 | |
| Graham number | 33.29 | 34.81 | 15.45 | 24.69 | 30.93 | |
| ROIC | -0.13 | -0.26 | -0.06 | -0.14 | -0.38 | |
| Return on tangible assets | -0.12 | -0.22 | -0.05 | -0.09 | -0.21 | |
| Graham Net | 16.4 | 12.71 | 13.69 | 9.56 | 3.34 | |
| Working capital | 412.38M | 348.2M | 376.74M | 537.78M | 421.15M | |
| Tangible asset value | 486.37M | 405.01M | 396.73M | 356.43M | 262.1M | |
| Net current asset value | 411.58M | 347.54M | 376.74M | 267.23M | 98.93M | |
| Invested capital | 0.02 | 0.01 | 0 | 0.06 | 0.07 | |
| Average receivables | 887.5K | 87K | 0 | 438K | 1.15M | |
| Average payables | 3.88M | 10.84M | 10.23M | 2.98M | 2.26M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 12.7 | 0 | 0 | 5.06 | 50.35 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 28.74 | 0 | 0 | 72.12 | 7.25 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.13 | -0.24 | -0.05 | -0.16 | -0.49 | |
| Capex per share | -0.04 | -0.03 | -0.02 | -0.05 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.05 | 0.24 | 0.05 | 0.13 | 0.12 | |
| Net income per share | -1.32 | -0.93 | -1.73 | -1.5 | -1.41 | |
| Operating cash flow per share | -0.63 | -0.38 | -0.88 | -0.95 | -1.37 | |
| Free cash flow per share | -0.63 | -0.38 | -0.89 | -0.96 | -1.38 | |
| Cash per share | 15.66 | 15.51 | 15.42 | 16.13 | 15.56 | |
| Book value per share | 9.81 | 9.21 | 6.84 | 5.57 | 4.53 | |
| Tangible book value per share | 9.81 | 9.21 | 6.84 | 5.57 | 4.53 | |
| Share holders equity per share | 9.81 | 9.21 | 6.84 | 5.57 | 4.53 | |
| Interest debt per share | 0.92 | 0.83 | 0.84 | 0.86 | 0.85 | |
| Market cap | 721.65M | 881.54M | 608.26M | 541.63M | 476.77M | |
| Enterprise value | 682.94M | 829.68M | 532.75M | 525.08M | 468.71M | |
| P/E ratio | -4.83 | -8.34 | -3.14 | -3.4 | -3.19 | |
| Price to sales ratio | 558.12 | 129.49 | 442.69 | 156.54 | 143.69 | |
| POCF ratio | -40.66 | -82.5 | -24.76 | -21.32 | -13.07 | |
| PFCF ratio | -40.55 | -81.17 | -24.58 | -21.16 | -13.01 | |
| P/B Ratio | 2.6 | 3.36 | 3.18 | 3.65 | 3.96 | |
| PTB ratio | 2.6 | 3.36 | 3.18 | 3.65 | 3.96 | |
| EV to sales | 528.19 | 121.87 | 387.74 | 151.76 | 141.26 | |
| Enterprise value over EBITDA | -25.5 | -37.48 | -13.35 | -15.05 | -14.52 | |
| EV to operating cash flow | -38.48 | -77.65 | -21.68 | -20.67 | -12.85 | |
| EV to free cash flow | -38.37 | -76.4 | -21.53 | -20.51 | -12.79 | |
| Earnings yield | -0.05 | -0.03 | -0.08 | -0.07 | -0.08 | |
| Free cash flow yield | -0.02 | -0.01 | -0.04 | -0.05 | -0.08 | |
| Debt to equity | 0.07 | 0.07 | 0.1 | 0.13 | 0.15 | |
| Debt to assets | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | |
| Net debt to EBITDA | 1.45 | 2.34 | 1.89 | 0.47 | 0.25 | |
| Current ratio | 21.39 | 17.16 | 12.21 | 10.53 | 10.92 | |
| Interest coverage | -4.83 | -6.11 | -10.24 | -9.21 | -8.52 | |
| Income quality | 0.53 | 0.4 | 0.56 | 0.64 | 0.98 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 6.85 | 1.38 | 7.87 | 3.09 | 3.07 | |
| Research and developement to revenue | 17.06 | 3.43 | 25.44 | 9.52 | 9.31 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.02 | 0.01 | 0.01 | 0 | |
| Capex to revenue | -0.04 | -0.03 | -0.13 | -0.05 | -0.05 | |
| Capex to depreciation | -0.09 | -0.29 | -0.3 | -0.32 | -0.27 | |
| Stock based compensation to revenue | 4.85 | 0.98 | 6.45 | 2.44 | 2.35 | |
| Graham number | 17.08 | 13.87 | 16.33 | 13.7 | 11.98 | |
| ROIC | -0.1 | -0.09 | -0.21 | -0.24 | -0.27 | |
| Return on tangible assets | -0.06 | -0.04 | -0.09 | -0.08 | -0.08 | |
| Graham Net | 3.64 | 3.31 | 2.56 | 2.37 | 1.83 | |
| Working capital | 429.38M | 421.15M | 401.36M | 396.9M | 388.82M | |
| Tangible asset value | 277.62M | 262.1M | 191.09M | 148.45M | 120.38M | |
| Net current asset value | 109.56M | 98.93M | 76.46M | 69.89M | 61.06M | |
| Invested capital | 0.07 | 0.07 | 0.1 | 0.13 | 0.15 | |
| Average receivables | 1.11M | 1.3M | 1.47M | 2.35M | 3.23M | |
| Average payables | 2.3M | 2.9M | 2.98M | 3.96M | 5.64M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 82.13 | 18.76 | 99.76 | 82.77 | 88.67 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1.1 | 4.8 | 0.9 | 1.09 | 1.01 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.13 | -0.1 | -0.25 | -0.27 | -0.31 | |
| Capex per share | 0 | -0.01 | -0.01 | -0.01 | -0.01 |
ANAB Frequently Asked Questions
What is AnaptysBio, Inc. stock symbol ?
AnaptysBio, Inc. is a US stock , located in San diego of Ca and trading under the symbol ANAB
Is AnaptysBio, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $32. The lowest prediction is $32 and the highest is $32
What is ANAB stock prediction ?
What is AnaptysBio, Inc. stock quote today ?
AnaptysBio, Inc. stock price is $16.49 today.
Is AnaptysBio, Inc. stock public?
Yes, AnaptysBio, Inc. is a publicly traded company.
Company Profile
- Volume Average 232.2K
- Market Capitalization 434.77M
- Employee 96
- CEO Mr. Daniel R. Faga
- Headquarters San Diego,CA,US
- IPO Date 2017-01-26
-
Website
https://www.anaptysbio.com 
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
